ECCO 2026

Precision medicine - from a static to a dynamic system

Early treatment concepts with infliximab

IL-23 - is this the good-bye from systemic therapy?

What is the best post-operative strategy in CD?

Fistulizing disease - what can we do better?

Deeper endpoints in clincial trials and RW

Update on upadacitinib vs. risankizumab after anti-TNF…

Evolving landscape of anti-fibrotic therapy in IBD

Diet as prevention and early intervention in Crohn’s…

Long-term data on colorectal cancer risk in modern IBD…

Stop of thiopurines in patients on subcutaneous…

Molecular medicine driving treatment decisioning!?

What is the best treatment approach in IBD?

Should we stop thiopurines in IBD patients who are…

Switching to subcutaneous infliximab is safe as a…

Top-down- versus Step-up-Therapie beim Morbus Crohn

Molekulare Medizin als Wegweiser für…

Θα πρέπει να σταματήσουμε τις θειοπουρίνες σε ασθενείς…

Should we prevent or treat post-operative recurrence in…

Long-term risankizumab persistence

Do we need immediate postoperative prophylaxis?

LIR!C 10 yrs FUP: Is there a benefit for surgery?

JAK–STAT inhibition as a therapeutic approach for…

Top-down vs. step-up therapy in CD

Früher Einsatz von Infliximab verbessert das…

Faut-il prévenir ou traiter la récidive postopératoire…

Is onmiddellijke postoperatieve preventie nodig?

JAK-STAT Hemmung zur Fistel-Therapie

Top-down vs. Step-up Therapie beim Morbus Crohn

Long term outcomes after appendicectomy in UC (5 year…

ASUC: smarter use of third-line rescue therapy

Treat-2-target strategy in UC

Combination therapy with tofacitinib and…

Steroid sparing effect of filgotinib in UC

Strategia treat-to-target nella colite ulcerosa

Tofacitinib-Steroid-Kombination bei ASUC

Effetto steroid-sparing di filgotinib nella colite…

Pouchchirurgie: enkel voor expertisecentra

Resultados a largo plazo tras apendicectomía en colitis…

Long-term outcomes of IL‑23 inhibitors

Obefazimod as antifibrotic agent

Langetermijn data van IL‑23 inhibitoren

Obefazimod come agente antifibrotico

UPA vs RISA in Crohn’s disease – a decision dilemma

Ustekinumab is effective and safe for paediatric…

Guselkumab – does it treat only the gut?

Histo-endoscopic outcomes of upadacitinib in CD

Guselkumab may improve and prevent extraintestinal…

Το ustekinumab είναι αποτελεσματικό και ασφαλές σε…

Guselkumab a objawy pozajelitowe

Nicht nur im Darm – Wirksamkeit von Guselkumab bei…

UPA vs RISA w chorobie Leśniowskiego-Crohna – sztuka…

Short term transmural healing detected by US in CD…

Vedolizumab combined with upadacitinib vs Vedolizumab…

Early and durable response with guselkumab

Histo-endoscopic outcomes of guselkumab in UC

Etrasimod efficacy in mildly-to-moderately active UC…

Long-term efficacy and safety of risankizumab in UC

Does colectomy reduce the risk of death in UC?

Etrasimod in the milder moderate UC patients

Mirikizumab is able to induce disease clearence in…

Efficacy and safety of vedolizumab + upadacitinib as…

Early symptomatic response with IL-23 blockers

Frühes symptomatisches Ansprechen unter IL-23-Blockade

Efficacia di Etrasimod in pazienti affetti da colite…

Efficacia e sicurezza a lungo termine di risankizumab…

Efficacia e sicurezza di vedolizumab + upadacitinib…

Efectividad y seguridad a corto plazo de Mirikizumab en…

Vedolizumab combinado con upadacitinib vs Vedolizumab…

Est-ce que la colectomie réduit le risque de décès dans…

Icotrokinra and systemic inflammatory burden in UC

The STENOVA Trial. Ontunisertib shows promising results…

Ontunisertib - ALK5 blockage in fistulizing CD

Appendectomy - a new therapeutic option in UC

AGMB-129, Ontunisertib, new MoA in patients with…

B-cells step into the spotlight

Cytotoxic CD4+ accumulate in the UC but not CD mucosa…

תאי B במרכז העניינים

Η μελέτη STENOVA: Το ontunisertib δείχνει υποσχόμενα…

Ontunisertib – ALK5-Blockade bei fistulierendem Morbus…

AGMB-129, Ontunisertib, nueva terapia para pacientes…

L’accumulo di cellule citotossiche CD4+ caratterizza la…

Impact de l’icotrokinra sur les biomarqueurs dans la…

Ikotrokinkra a stan zapalny w colitis ulcerosa

ADHD and autism in IBD – the same or different story?

IBDMED going global!

IBDMED מעבר לאזור הים התיכון